The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection
Open accessAbstract
Depo-provera, a long-acting progestational formulation, is widely used to facilitate infection of sexually transmitted diseases in animal models. We have previously reported that hormone treatments change susceptibility and immune responses to genital tract infections. In this study we compared the changes in susceptibility of mice to genital herpes simplex virus type 2 (HSV-2) after Depo-provera or a saline suspension of progesterone (P-sal). We found that following Depo-provera-treatment, mice had prolonged diestrus that lasted more than 4 weeks. This coincided with a 100-fold increase in susceptibility to genital HSV-2 compared to that of untreated mice. Mice given P-sal were in diestrous stage for 4 to 6 days before returning to irregular reproductive cycles. When these mice were infected at diestrus they showed a 10-fold increase in susceptibility compared to that of normal, untreated mice. P-sal-treated mice infected at estrus were susceptible to HSV-2, depending on the infectious dose. Normal, untreated mice in estrus were not susceptible to HSV-2, even at a high infectious dose of 10 7 PFU. In addition to alterations in susceptibility, Depo-provera treatment had inhibitory effects on immune responses to HSV-2. Mice immunized with HSV-2 protein (gB) and treated with Depo-provera showed significant lowering of local HSV-2-specific immunoglobulin G (IgG) and IgA in their vaginal washes. Mice immunized with an attenuated strain of HSV-2 2 weeks after Depo-provera treatment failed to develop protection when challenged intravaginally with wild-type HSV-2. In contrast, mice given progesterone and immunized at diestrus or estrus were completely protected from intravaginal challenge. These studies show that Depo-provera treatment changes susceptibility and local immune responses to genital HSV-2 infection. Animal models and vaccine strategies for sexually transmitted diseases need to consider the effect of hormone treatments on susceptibility and immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progesterone implants enhance SIV vaginal transmission and early virus load
Marx, P. A., Spira, A. I., Gettie, A., Dailey, P. J., Veazey, R. S., Lackner, A. A., Mahoney, C. J., Miller, C. J., Claypool, L. E., Ho, D. D., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1084 · Cited by 465
Martin, Jr., Nyange, P. M., Richardson, B. A., Lavreys, L., Mandaliya, K., Jackson, D. J., Ndinya‐Achola, J. O., & Kreiss, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/515654 · Cited by 269
Gallichan, W. S., & Rosenthal, K. L. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1879 · Cited by 238
Self-citationA mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr, M. B., Kepple, L., McDermott, M. R., Drew, M. D., Bozzola, J. J., & Parr, E. L. (1994) · PubMed · Cited by 237
White, H. D., Crassi, K. M., Givan, A. L., Stern, J. E., Gonzalez, J. L., Memoli, V. A., Green, W. R., & Wira, C. R. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.3017 · Cited by 232
Gallichan, W. S., Woolstencroft, R. N., Guarasci, T., McCluskie, M. J., Davis, H. L., & Rosenthal, K. L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3451 · Cited by 220
Self-citationUnique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium
Yeaman, G. R., Guyre, P. M., Fanger, M. W., Collins, J. E., White, H. D., Rathbun, W., Orndorff, K. A., Gonzalez, J., Stern, J. E., & Wira, C. R. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.61.4.427 · Cited by 195
Estrogen Protects against Vaginal Transmission of Simian Immunodeficiency Virus
Smith, S. M., Baskin, G. B., & Marx, P. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315776 · Cited by 165
Kaushic, C., Zhou, F., Murdin, A. D., et al. (2000) · Infection and Immunity · doi:10.1128/iai.68.7.4207-4216.2000 · Cited by 157
Self-citationGallichan, W. S., & Rosenthal, K. L. (1998) · The Journal of Infectious Diseases · doi:10.1086/515286 · Cited by 133
Self-citation
Cited by
Maternal and Neonatal Herpes Simplex Virus Infections
Corey, L., & Wald, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0807633 · Cited by 421
Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus
Ensign, L. M., Tang, B. C., Wang, Y.-Y., Tse, T. A., Hoen, T., Cone, R., & Hanes, J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003453 · Cited by 368
Why consider vaginal drug administration?
Alexander, N. J., Baker, E., Kaptein, M., Karck, U., Miller, L., & Zampaglione, E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.01.025 · Cited by 269
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection
Steinbach, J. M., Weller, C. E., Booth, C. J., & Saltzman, W. M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.008 · Cited by 113
Metadata
- Authors
- Kaushic, C., Ashkar, A. A., Reid, L. A., & Rosenthal, K. L.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2003-04-15
- Volume
- 77
- Issue
- 8
- Pages
- 4558-4565
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2101604556
- Cited by
- 267
- References
- 14
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection. https://app.cochat.ai/papers/10.1128/jvi.77.8.4558-4565.2003
- The paper
- Kaushic, C., Ashkar, A. A., Reid, L. A., & Rosenthal, K. L. (2003). Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection. Journal of Virology. https://doi.org/10.1128/jvi.77.8.4558-4565.2003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.